Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant

Olga J. A. E. Ophorst; Katarina Radosevic; Jaco M. Klap; Jeroen Sijtsma; Gert Gillissen; Ratna Mintardjo; Mark J. M. van Ooij; Lennart Holterman; Arjen Companjen; Jaap Goudsmit; Menzo J. E. Havenga

doi:10.1016/j.vaccine.2007.06.019

Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant

Olga J. A. E. Ophorst
, Katarina Radosevic
, Jaco M. Klap
, Jeroen Sijtsma
, Gert Gillissen
, Ratna Mintardjo
, Mark J. M. van Ooij
, Lennart Holterman
, Arjen Companjen
, Jaap Goudsmit
, Menzo J. E. Havenga

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Previously, we have shown the potency of recombinant Adenovirus serotype 35 viral vaccines (rAd35) to induce strong immune response against the circumsporozoite protein (CS) of the plasmodium parasite. To further optimize immunogenicity of Ad35-based malaria vaccines we formulated rAd35.CS vaccine with aluminium phosphate adjuvant (AlPO(4)). In contrast to the conventional protein based vaccines no absorption to aluminium adjuvant was observed and rAd35 viral in vitro infectivity in mammalian cells was preserved. Immunization with Ad35.CS formulated with AlPO(4) resulted in significantly higher CS specific T and B cell responses in mice upon either single or prime-boost vaccination regimens as compared to rAd35.CS alone. With these results we report for the first time the feasibility of using an AlPO(4) adjuvant to increase the potency of a live adenovirus serotype 35-based vaccine

Original language	English
Pages (from-to)	6501-6510
Journal	Vaccine
Volume	25
Issue number	35
DOIs	https://doi.org/10.1016/j.vaccine.2007.06.019
Publication status	Published - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.vaccine.2007.06.019

Cite this

Ophorst, O. J. A. E., Radosevic, K., Klap, J. M., Sijtsma, J., Gillissen, G., Mintardjo, R., van Ooij, M. J. M., Holterman, L., Companjen, A., Goudsmit, J., & Havenga, M. J. E. (2007). Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine, 25(35), 6501-6510. https://doi.org/10.1016/j.vaccine.2007.06.019

@article{5627f0feb83b403daf1d803298b31c33,

title = "Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant",

abstract = "Previously, we have shown the potency of recombinant Adenovirus serotype 35 viral vaccines (rAd35) to induce strong immune response against the circumsporozoite protein (CS) of the plasmodium parasite. To further optimize immunogenicity of Ad35-based malaria vaccines we formulated rAd35.CS vaccine with aluminium phosphate adjuvant (AlPO(4)). In contrast to the conventional protein based vaccines no absorption to aluminium adjuvant was observed and rAd35 viral in vitro infectivity in mammalian cells was preserved. Immunization with Ad35.CS formulated with AlPO(4) resulted in significantly higher CS specific T and B cell responses in mice upon either single or prime-boost vaccination regimens as compared to rAd35.CS alone. With these results we report for the first time the feasibility of using an AlPO(4) adjuvant to increase the potency of a live adenovirus serotype 35-based vaccine",

author = "Ophorst, \{Olga J. A. E.\} and Katarina Radosevic and Klap, \{Jaco M.\} and Jeroen Sijtsma and Gert Gillissen and Ratna Mintardjo and \{van Ooij\}, \{Mark J. M.\} and Lennart Holterman and Arjen Companjen and Jaap Goudsmit and Havenga, \{Menzo J. E.\}",

year = "2007",

doi = "10.1016/j.vaccine.2007.06.019",

language = "English",

volume = "25",

pages = "6501--6510",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "35",

}

TY - JOUR

T1 - Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant

AU - Ophorst, Olga J. A. E.

AU - Radosevic, Katarina

AU - Klap, Jaco M.

AU - Sijtsma, Jeroen

AU - Gillissen, Gert

AU - Mintardjo, Ratna

AU - van Ooij, Mark J. M.

AU - Holterman, Lennart

AU - Companjen, Arjen

AU - Goudsmit, Jaap

AU - Havenga, Menzo J. E.

PY - 2007

Y1 - 2007

N2 - Previously, we have shown the potency of recombinant Adenovirus serotype 35 viral vaccines (rAd35) to induce strong immune response against the circumsporozoite protein (CS) of the plasmodium parasite. To further optimize immunogenicity of Ad35-based malaria vaccines we formulated rAd35.CS vaccine with aluminium phosphate adjuvant (AlPO(4)). In contrast to the conventional protein based vaccines no absorption to aluminium adjuvant was observed and rAd35 viral in vitro infectivity in mammalian cells was preserved. Immunization with Ad35.CS formulated with AlPO(4) resulted in significantly higher CS specific T and B cell responses in mice upon either single or prime-boost vaccination regimens as compared to rAd35.CS alone. With these results we report for the first time the feasibility of using an AlPO(4) adjuvant to increase the potency of a live adenovirus serotype 35-based vaccine

AB - Previously, we have shown the potency of recombinant Adenovirus serotype 35 viral vaccines (rAd35) to induce strong immune response against the circumsporozoite protein (CS) of the plasmodium parasite. To further optimize immunogenicity of Ad35-based malaria vaccines we formulated rAd35.CS vaccine with aluminium phosphate adjuvant (AlPO(4)). In contrast to the conventional protein based vaccines no absorption to aluminium adjuvant was observed and rAd35 viral in vitro infectivity in mammalian cells was preserved. Immunization with Ad35.CS formulated with AlPO(4) resulted in significantly higher CS specific T and B cell responses in mice upon either single or prime-boost vaccination regimens as compared to rAd35.CS alone. With these results we report for the first time the feasibility of using an AlPO(4) adjuvant to increase the potency of a live adenovirus serotype 35-based vaccine

U2 - 10.1016/j.vaccine.2007.06.019

DO - 10.1016/j.vaccine.2007.06.019

M3 - Article

C2 - 17646036

SN - 0264-410X

VL - 25

SP - 6501

EP - 6510

JO - Vaccine

JF - Vaccine

IS - 35

ER -

Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this